Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform
- Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focused investors - Proceeds to be used…...
Read MoreQuell Therapeutics Announces Participation in Upcoming Investor Conferences
London, UK and Boston, MA – November 22, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that management will…...
Read MoreQuell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy
First clinical trial will investigate QEL-001 as a novel treatment to prevent organ rejection in liver transplant patients and eliminate the need for lifelong systemic immunosuppression London, UK and Boston, MA, USA – October 27, 2021 – Quell Therapeutics Ltd (“Quell”),…...
Read MoreQuell Therapeutics Presents New Data Demonstrating the Ability of its Proprietary Phenotype Lock Technology to Enhance the Safety, Stability and Efficacy of Engineered Treg Therapies
Quell’s phenotype lock technology is a core element of its multi-modular engineered Treg platformLocks Treg cells in a potently suppressive phenotype and prevents switch to potentially pathogenic effector phenotypesPreclinical data presented at the European Society of Gene & Cell Therapy…...
Read MoreQuell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult
Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell’s pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and autoimmunity London, UK – September 23, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader…...
Read MoreQuell Therapeutics to Present at the 2021 Wedbush Pacgrow Healthcare Virtual Conference
London, UK and Boston, MA, USA, August 4, 2021 – Quell Therapeutics Ltd (“Quell”), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today announced that Iain McGill, Chief Executive…...
Read MoreQuell Therapeutics Appoints Tracey Lodie, Ph.D., as Chief Scientific Officer
Dr. Hartl, former Therapeutic Area Head – Autoimmunity/Transplantation/Inflammation at Novartis Institutes for Biomedical Research (NIBR), to lead Quell's innovative multi-modular Treg cell therapy programs into clinical development LONDON and BOSTON, July 29, 2021 - Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered…...
Read MoreQuell Therapeutics Appoints Dominik Hartl, M.D., as Chief Medical Officer
Dr. Hartl, former Therapeutic Area Head – Autoimmunity/Transplantation/Inflammation at Novartis Institutes for Biomedical Research (NIBR), to lead Quell's innovative multi-modular Treg cell therapy programs into clinical development LONDON, July 22, 2021 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered…...
Read MoreBioCentury – Quell: tweaking Tregs for persistence, potency and stability
London-based Quell is among a new generation of companies springboarding off advances in CAR T cells and gene editing to develop more targeted Treg cell therapies with enhanced persistence, potency and stability. To view the full article please click here...
Read More